Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX) — Form SCHEDULE 13G: Ownership over 5% (passive)
About this filing
Protalix BioTherapeutics, Inc. (PLX) filed Form SCHEDULE 13G (ownership over 5% (passive)) with the SEC on Oct 15, 2026. A Schedule 13G reports a passive investor owning more than 5% of the company.
Key facts
- Document
- —
More PLX filings
- 4
Filed Sep 9, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
- 4
Filed Sep 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.